KPTI - Karyopharm's selinexor data from late-stage soft tissue cancer study in oral presentation

Karyopharm Therapeutics ([[KPTI]] -1.5%) has announced presentation of positive results from the Phase 3 portion of SEAL study evaluating single agent, oral XPOVIO (selinexor) versus matching placebo in patients with liposarcoma at the Connective Tissue Oncology Society 2020 Annual Meeting. Plans to submit US marketing application during Q1 of 2021.As previously reported, the SEAL study met its primary endpoint of a statistically significant increase in median progression-free survival ((PFS)) in patients with at least two prior therapies.Median PFS in the XPOVIO arm was 2.83 months compared to 2.07 months in the placebo arm (hazard ratio=0.70). Data indicates that XPOVIO reduced the risk of disease progression or death by ~30%, compared to placebo.Estimated 6-month PFS survival probability was 23.9% in selinexor arm compared to 13.9% on placebo, with 12-month PFS survival probability of 8.4% compared to 2%.Also, data suggested that 7.5% of patients on the selinexor arm had more than 15% reduction

For further details see:

Karyopharm's selinexor data from late-stage soft tissue cancer study in oral presentation